Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08AWI
|
|||
| Former ID |
DCL000937
|
|||
| Drug Name |
PRX-00023
|
|||
| Synonyms |
Naluzotan; 740873-06-7; PRX-00023; UNII-LQ54E5B4EW; LQ54E5B4EW; CHEMBL209821; Naluzotan [USAN:INN]; PRX 00023; Naluzotan (USAN/INN); SCHEMBL678016; ZINC3963096; BCP20177; BDBM50187377; CS-6740; SB16847; N-[3-[4-[4-(cyclohexylmethylsulfonylamino)butyl]piperazin-1-yl]phenyl]acetamide; HY-14848; AN-27536; D09358; L001689; 833C676; Acetamide, N-(3-(4-(4-(((cyclohexylmethyl)sulfonyl)amino)butyl)-1-piperazinyl)phenyl)-; N-(3-[4-(4-Cyclohexylmethanesulfonylaminobutyl)piperazin-1-yl]phenyl)acetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Mood disorder [ICD-11: 6A60-6E23; ICD-9: 296] | Discontinued in Phase 2 | [1] | |
| Company |
Epix
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H38N4O3S
|
|||
| Canonical SMILES |
CC(=O)NC1=CC(=CC=C1)N2CCN(CC2)CCCCNS(=O)(=O)CC3CCCCC3
|
|||
| InChI |
1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
|
|||
| InChIKey |
SPWZXWDPAWDKQE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 740873-06-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Modulator | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. | |||
| REF 2 | PRX-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety.Pharmacol Biochem Behav.2009 Nov;94(1):8-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.